Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Neumann Franz Josef) "

Sökning: WFRF:(Neumann Franz Josef)

  • Resultat 1-10 av 22
  • [1]23Nästa
Sortera/gruppera träfflistan
  • Chau, Katherine H, et al. (författare)
  • Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity: Analysis From ADAPT-DES.
  • 2021
  • Ingår i: JACC. Cardiovascular interventions. - 1876-7605.
  • Tidskriftsartikel (refereegranskat)abstract
    • The aim of this study was to determine the risk period for increased stent thrombosis (ST) after percutaneous coronary intervention (PCI) in patients with acute coronary syndromes (ACS) and whether this increased risk is related to high platelet reactivity (HPR).ST risk after PCI is higher among patients with ACS than those with stable ischemic heart disease. When ST risk is highest in patients with ACS and how that is affected by HPR is unknown.Using the ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) registry, ST rates during 2-year follow-up post-PCI with drug-eluting stents were compared among patients presenting with ACS (myocardial infarction [MI] or unstable angina) or stable ischemic heart disease (non-ACS). Landmark analyses were done at 30 days and 1 year post-PCI. Platelet reactivity on aspirin and clopidogrel post-PCI was assessed using VerifyNow assays.Of 8,582 patients, 2,063 presented with MI, 2,370 with unstable angina, and 4,149 with non-ACS. Incidence rates of HPR were 48.0%, 43.3%, and 39.8%, respectively (p < 0.001). Within the first 30 days post-PCI, patients presenting with MI had increased ST risk compared with patients with non-ACS (hazard ratio [HR]: 4.52; 95% confidence interval [CI]: 2.01 to 10.14; p < 0.001). After 30 days, relative ST risks were progressively lower and no longer significant between groups (31 days to 1 year post-PCI: HR: 1.97; 95% CI: 0.80 to 4.85; >1 year post-PCI: HR: 0.89; 95% CI: 0.27 to 2.92). The elevated ST risk in patients with MI within 30 days was largely confined to those with HPR on clopidogrel (HR: 5.77; 95% CI: 2.13 to 15.63; p < 0.001).Among patients undergoing PCI, rates of ST during 2-year follow-up were highest in those with MI and lowest in those with non-ACS. Increased ST risk in patients with MI was greatest in the first 30 days post-PCI and was observed predominantly among those with increased HPR on clopidogrel. These findings emphasize the importance of adequate P2Y12 inhibition after MI, especially within the first 30 days after stent implantation.
  • Chieffo, Alaide, et al. (författare)
  • EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic
  • 2020
  • Ingår i: EuroIntervention. - : EUROPA EDITION. - 1774-024X .- 1969-6213. ; 41:19, s. 1839-1851
  • Tidskriftsartikel (refereegranskat)abstract
    • The coronavirus disease 2019 (COVID-19) pandemic poses an unprecedented challenge to healthcare worldwide. The infection can be life threatening and require intensive care treatment. The transmission of the disease poses a risk to both patients and healthcare workers. The number of patients requiring hospital admission and intensive care may overwhelm health systems and negatively affect standard care for patients presenting with conditions needing emergency interventions. This position statements aims to assist cardiologists in the invasive management of acute coronary syndrome (ACS) patients in the context of the COVID-19 pandemic. To that end, we assembled a panel of interventional cardiologists and acute cardiac care specialists appointed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and from the Acute Cardiovascular Care Association (ACVC) and included the experience from the first and worst affected areas in Europe. Modified diagnostic and treatment algorithms are proposed to adapt evidence-based protocols for this unprecedented challenge. Various clinical scenarios, as well as management algorithms for patients with a diagnosed or suspected COVID-19 infection, presenting with ST- and non-ST-segment elevation ACS are described. In addition, we address the need for re-organization of ACS networks, with redistribution of hub and spoke hospitals, as well as for in-hospital reorganization of emergency rooms and cardiac units, with examples coming from multiple European countries. Furthermore, we provide a guidance to reorganization of catheterization laboratories and, importantly, measures for protection of healthcare providers involved with invasive procedures.
  • Chin, Chee Tang, et al. (författare)
  • The Compare-Acute trial of fractional flow reserve-guided multivessel angioplasty in myocardial infarction
  • 2017
  • Ingår i: EuroIntervention. - : Société Europa Edition. - 1774-024X. ; 13:5, s. 613-616
  • Tidskriftsartikel (refereegranskat)abstract
    • The Compare-Acute trial demonstrates the relative safety and utility of performing multivessel FFR to examine the significance of non-culprit lesions during primary PCI. Patients who had an FFR-guided PCI strategy for non-culprit lesions during the index hospitalisation had fewer adverse cardiovascular events, essentially unplanned revascularisations, as compared to patients who were treated for the infarct-related artery only.
  • Jander, Nikolaus, et al. (författare)
  • Indexing aortic valve area by body surface area increases the prevalence of severe aortic stenosis
  • 2014
  • Ingår i: Heart. - : BMJ Publishing Group. - 1355-6037 .- 1468-201X. ; 100:1, s. 28-33
  • Tidskriftsartikel (refereegranskat)abstract
    • Background To account for differences in body size in patients with aortic stenosis, aortic valve area (AVA) is divided by body surface area (BSA) to calculate indexed AVA (AVA(index)). Cut-off values for severe stenosis are <1.0cm(2) for AVA and <0.6cm(2)/m(2) for AVA(index). Objective To investigate the influence of indexation on the prevalence of severe aortic stenosis and on the predictive accuracy regarding clinical outcome. Methods Echocardiographic and anthropometric data from a retrospective cohort of 2843 patients with aortic stenosis (jet velocity >2.5m/s) and from 1525 patients prospectively followed in the simvastatin and ezetimibe in aortic stenosis (SEAS) trial were analysed. Results The prevalence of severe stenosis increased with the AVA(index) criterion compared to AVA from 71% to 80% in the retrospective cohort, and from 29% to 44% in SEAS (both p<0.001). Overall, the predictive accuracy for aortic valve events was virtually identical for AVA and AVA(index) in the SEAS population (mean follow-up of 46months; area under the receiver operating characteristic curve: 0.67 (95% CI 0.64 to 0.70) vs 0.68 (CI 0.65 to 0.71) (NS). However, 213 patients additionally categorised as severe by AVA(index) experienced significantly less valve related events than those fulfilling only the AVA criterion (p<0.001). Conclusions Indexing AVA by BSA (AVA(index)) significantly increases the prevalence of patients with criteria for severe stenosis by including patients with a milder degree of the disease without improving the predictive accuracy for aortic valve related events.
  • Jander, Nikolaus, et al. (författare)
  • Outcome of Patients With Low-Gradient "Severe" Aortic Stenosis and Preserved Ejection Fraction
  • 2011
  • Ingår i: Circulation. - : Lippincott Williams & Wilkins. - 1524-4539 .- 0009-7322. ; 123:8, s. 887-895
  • Tidskriftsartikel (refereegranskat)abstract
    • Background-Retrospective studies have suggested that patients with a low transvalvular gradient in the presence of an aortic valve area <1.0 cm(2) and normal ejection fraction may represent a subgroup with an advanced stage of aortic valve disease, reduced stroke volume, and poor prognosis requiring early surgery. We therefore evaluated the outcome of patients with low-gradient "severe" stenosis (defined as aortic valve area < 1.0 cm(2) and mean gradient <= 40 mm Hg) in the prospective Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Methods and Results-Outcome in patients with low-gradient "severe" aortic stenosis was compared with outcome in patients with moderate stenosis (aortic valve area 1.0 to 1.5 cm(2); mean gradient 25 to 40 mm Hg). The primary end point of aortic valve events included death from cardiovascular causes, aortic valve replacement, and heart failure due to aortic stenosis. Secondary end points were major cardiovascular events and cardiovascular death. In 1525 asymptomatic patients (mean age, 67 +/- 10 years; ejection fraction, >= 55%), baseline echocardiography revealed low-gradient severe stenosis in 435 patients (29%) and moderate stenosis in 184 (12%). Left ventricular mass was lower in patients with low-gradient severe stenosis than in those with moderate stenosis (182 +/- 64 versus 212 +/- 68 g; P < 0.01). During 46 months of follow-up, aortic valve events occurred in 48.5% versus 44.6%, respectively (P=0.37; major cardiovascular events, 50.9% versus 48.5%, P=0.58; cardiovascular death, 7.8% versus 4.9%, P=0.19). Low-gradient severe stenosis patients with reduced stroke volume index (<= 35 mL/m(2); n=223) had aortic valve events comparable to those in patients with normal stroke volume index (46.2% versus 50.9%; P=0.53). Conclusions-Patients with low-gradient "severe" aortic stenosis and normal ejection fraction have an outcome similar to that in patients with moderate stenosis. (Circulation. 2011;123:887-895.)
  • Jander, Nikolaus, et al. (författare)
  • Velocity ratio predicts outcomes in patients with low gradient severe aortic stenosis and preserved EF
  • 2014
  • Ingår i: Heart. - 1355-6037 .- 1468-201X. ; 100:24, s. 1946-1953
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective To evaluate the usefulness of velocity ratio (VR) in patients with low gradient severe aortic stenosis (LGSAS) and preserved EF.Background LGSAS despite preserved EF represents a clinically challenging entity. Reliance on mean pressure gradient (MPG) may underestimate stenosis severity as has been reported in the context of paradoxical low flow, LGSAS. On the other hand, grading of stenosis severity by aortic valve area (AVA) may overrate stenosis severity due to erroneous underestimation of LV outflow tract (LVOT) diameter, small body size or inconsistencies in cut-off values for severe stenosis. We hypothesised that VR may have conceptual advantages over MPG and AVA, predict clinical outcomes and thereby be useful in the management of patients with LGSAS.Methods Patients from the prospective Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study with an AVA<1.0 cm(2), MPG <= 40 mm Hg and EF >= 55% and asymptomatic at baseline were stratified according to VR with a cut-off value of 0.25. Outcomes were evaluated according to aortic valve-related events and cardiovascular death.Results Of 435 patients with LGSAS, 197 (45%) had VR<0.25 suggesting severe and 238 (55%) had VR >= 0.25 suggesting non-severe stenosis. Aortic valve-related events (mean follow-up 42 +/- 14 months) were more frequent in patients with VR<0.25 (57% vs 41%; p<0.001) as was cardiovascular death within the first 24 months (p<0.05). In multivariable Cox regression analysis, MPG was the strongest independent predictor of aortic valve events (p<0.001) followed by VR (p<0.02). Adjusting AVA by VR increased predictive accuracy for aortic valve events (area under the receiver operating curve 0.62 (95% CI 0.57 to 0.67) vs 0.56 (95% CI 0.51 to 0.61) for AVA, p=0.02) with net reclassification improvement calculated at 0.36 (95% CI 0.17 to 0.54, p<0.001). VR did not improve the prediction of clinical events by MPG.Conclusions In the difficult setting of LGSAS, VR shows a strong association with valve-related events and - although not outperforming MPG-may be particularly useful in guiding clinical management.
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 22
  • [1]23Nästa
Typ av publikation
tidskriftsartikel (21)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (20)
övrigt vetenskapligt (2)
Windecker, Stephan (10)
Collet, Jean-Philipp ... (8)
Roffi, Marco (7)
Kolh, Philippe (7)
Jüni, Peter (7)
Bueno, Héctor (6)
visa fler...
Valgimigli, Marco (6)
Boman, Kurt (5)
Huber, Kurt (5)
Montalescot, Gilles (5)
Steg, Philippe Gabri ... (5)
Pedersen, Terje R. (5)
Zamorano, Jose Luis (4)
Jeppsson, Anders, 19 ... (4)
Willenheimer, Ronnie (4)
Hamm, Christian W. (4)
Holme, Ingar (3)
Widimsky, Petr (3)
Knuuti, Juhani (3)
Dean, Veronica (3)
McDonagh, Theresa (3)
Halvorsen, Sigrun (3)
James, Stefan (3)
Egstrup, Kenneth (3)
Tendera, Michal (2)
Agewall, Stefan (2)
Torbicki, Adam (2)
Lancellotti, Patrizi ... (2)
Piepoli, Massimo F. (2)
James, Stefan, 1964- (2)
Stone, Gregg W. (2)
Armstrong, Paul W. (2)
Lopes, Renato D. (2)
Granger, Christopher ... (2)
Ezekowitz, Justin A (2)
Verheugt, Freek (2)
Weisz, Giora (2)
Roe, Matthew T (2)
Stebbins, Amanda (2)
Mahaffey, Kenneth W. (2)
Redfors, Björn (2)
Di Mario, Carlo (2)
Storey, Robert F. (2)
Mehran, Roxana (2)
Merkely, Bela (2)
Moliterno, David J. (2)
Danchin, Nicolas (2)
Auricchio, Angelo (2)
Newby, L Kristin (2)
Badimon, Lina (2)
visa färre...
Göteborgs universitet (8)
Uppsala universitet (8)
Umeå universitet (5)
Lunds universitet (5)
Karolinska Institutet (2)
Linnéuniversitetet (1)
Engelska (22)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (13)


pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy